Clinical Trials Browser

Phase 2/3 × INDUSTRY × Myelodysplastic Syndromes × Clear all

NCT04256317 2026-03-18

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02598661 2026-01-05

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Phase 2/3 Active not recruiting

289 enrolled 35 charts 1 FDA

Myeloid

Myelodysplastic Syndromes, Recurrence

NCT03699475 2023-09-29

THRIVE

Phase 2/3 Terminated

1 enrolled 9 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00967343 2021-06-14

Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Phase 2/3 Terminated

40 enrolled 10 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Leukemia, Myeloid, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma